Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INH vs 8-HOUR BAYER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
0-10% (low binding; primarily albumin).
80-90% bound to albumin; binding is concentration-dependent and saturable.
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
Oral: ~90%. Intramuscular: ~100%.
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
None
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INH vs 8-HOUR BAYER, answered by our medical review team.
INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. 8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INH and 8-HOUR BAYER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INH and 8-HOUR BAYER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.